1
|
Chatterjee P, Tegg M, Pedrini S, Fagan AM, Xiong C, Singh AK, Taddei K, Gardener S, Masters CL, Schofield PR, Multhaup G, Benzinger TLS, Morris JC, Bateman RJ, Greenberg SM, van Buchem MA, Stoops E, Vanderstichele H, Teunissen CE, Hankey GJ, Wermer MJH, Sohrabi HR, Martins RN. Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. Int J Mol Sci 2021; 22:ijms22062931. [PMID: 33805778 PMCID: PMC8000178 DOI: 10.3390/ijms22062931] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 03/06/2021] [Accepted: 03/07/2021] [Indexed: 01/10/2023] Open
Abstract
Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2) and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates, at both T1(Aβ1-40: p = 0.001; Aβ1-42: p = 0.0004) and T2 (Aβ1-40: p = 0.001; Aβ1-42: p = 0.016) employing the Single Molecule Array (Simoa) platform, however no significant differences were observed using the xMAP platform. Further, pairwise longitudinal analyses of plasma Aβ1-40 revealed decreased levels in MCs using data from the Simoa platform (p = 0.041) and pairwise longitudinal analyses of plasma Aβ1-42 revealed decreased levels in MCs using data from the xMAP platform (p = 0.041). Findings from the Simoa platform suggest that plasma Aβ may add value to a panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further validation studies in larger sample sets are required.
Collapse
Affiliation(s)
- Pratishtha Chatterjee
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Michelle Tegg
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Steve Pedrini
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Anne M. Fagan
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Chengjie Xiong
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
- Division of Biostatistics, Washington University, St. Louis, MO 63130, USA
| | - Abhay K. Singh
- Macquarie Business School, Macquarie University, North Ryde, NSW 2109, Australia;
| | - Kevin Taddei
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
| | - Samantha Gardener
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia;
| | - Peter R. Schofield
- Neuroscience Research Australia, Sydney, NSW 2031, Australia;
- School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia
| | - Gerhard Multhaup
- Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada;
| | - Tammie L. S. Benzinger
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
- Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - John C. Morris
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Randall J. Bateman
- Department of Neurology, Washington University, St. Louis, MO 63130, USA; (A.M.F.); (J.C.M.); (R.J.B.)
- Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO 63130, USA; (C.X.); (T.L.S.B.)
| | - Steven M. Greenberg
- Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston, MA 02114, USA;
| | - Mark A. van Buchem
- Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
| | | | | | - Charlotte E. Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, 1007 MB Amsterdam, The Netherlands;
| | - Graeme J. Hankey
- Faculty of Health and Medical Sciences, Medical School, The University of Western Australia, Crawley, WA 6009, Australia;
| | - Marieke J. H. Wermer
- Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;
| | - Hamid R. Sohrabi
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
- Centre for Healthy Ageing, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, WA 6150, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia
| | - Ralph N. Martins
- Department of Biomedical Sciences, Macquarie University, North Ryde, NSW 2109, Australia; (P.C.); (H.R.S.)
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; (M.T.); (S.P.); (K.T.); (S.G.)
- Australian Alzheimer’s Research Foundation, Nedlands, WA 6009, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia
- The KaRa Institute of Neurological Disease, Macquarie Park, NSW 2113, Australia
- Correspondence: ; Tel.: +61-8-6304-5456; Fax: +61-8-6304-5851
| | | |
Collapse
|
3
|
Nishitsuji K, Tomiyama T, Ishibashi K, Kametani F, Ozawa K, Okada R, Maat-Schieman ML, Roos RAC, Iwai K, Mori H. Cerebral vascular accumulation of Dutch-type Abeta42, but not wild-type Abeta42, in hereditary cerebral hemorrhage with amyloidosis, Dutch type. J Neurosci Res 2008; 85:2917-23. [PMID: 17628026 DOI: 10.1002/jnr.21413] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D), is an autosomal dominant disorder caused by the Dutch mutation (E693Q) in the beta-amyloid precursor protein. This mutation produces an aberrant amyloid beta (Abeta) species (AbetaE22Q) and causes severe meningocortical vascular Abeta deposition. We analyzed the Abeta composition of the vascular amyloid in the brains of HCHWA-D patients. Immunohistochemistry demonstrated that the vascular amyloid contained both Abeta40 and Abeta42, with a high Abeta40/Abeta42 ratio. In Western blotting of cerebral microvessel fractions isolated from the brains, both wild-type and Dutch-type Abeta40 were observed as major species. Reverse-phase HPLC-mass spectrometric analysis of the fractions revealed both wild-type and Dutch-type Abeta38 as the other main components of the vascular amyloid. Moreover, we detected peaks corresponding to Dutch-type Abeta42 but not to wild-type Abeta42. These results suggest a pathogenic role for the mutant Abeta42 in addition to the mutant Abeta40 in the cerebral amyloid angiopathy of HCHWA-D.
Collapse
Affiliation(s)
- Kazuchika Nishitsuji
- Department of Neuroscience, Osaka City University Graduate School of Medicine, Osaka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Hoos MD, Ahmed M, Smith SO, Van Nostrand WE. Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. J Biol Chem 2007; 282:9952-9961. [PMID: 17259179 DOI: 10.1074/jbc.m603494200] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Deposition of fibrillar amyloid beta-protein (Abeta) in the brain is a prominent pathological feature of Alzheimer disease and related disorders, including familial forms of cerebral amyloid angiopathy (CAA). Mutant forms of Abeta, including Dutch- and Iowa-type Abeta, which are responsible for familial CAA, deposit primarily as fibrillar amyloid along the cerebral vasculature and are either absent or present only as diffuse non-fibrillar plaques in the brain parenchyma. Despite the lack of parenchymal fibril formation in vivo, these CAA mutant Abeta peptides exhibit a markedly increased rate and extent of fibril formation in vitro compared with wild-type Abeta. Based on these conflicting observations, we sought to determine whether brain parenchymal factors that selectively interact with and modulate CAA mutant Abeta fibril assembly exist. Using a combination of immunoaffinity chromatography and mass spectrometry, we identified myelin basic protein (MBP) as a prominent brain parenchymal factor that preferentially binds to CAA mutant Abeta compared with wild-type Abeta. Surface plasmon resonance measurements confirmed that MBP bound more tightly to Dutch/Iowa CAA double mutant Abeta than to wild-type Abeta. Using a combination of biochemical and ultrastructural techniques, we found that MBP inhibited the fibril assembly of CAA mutant Abeta. Together, these findings suggest a possible role for MBP in regulating parenchymal fibrillar Abeta deposition in familial CAA.
Collapse
Affiliation(s)
- Michael D Hoos
- Department of Medicine, Stony Brook University, Stony Brook, New York 11794-8153
| | - Mahiuddin Ahmed
- Center for Structural Biology, Stony Brook University, Stony Brook, New York 11794-8153
| | - Steven O Smith
- Center for Structural Biology, Stony Brook University, Stony Brook, New York 11794-8153
| | | |
Collapse
|
8
|
Yamaguchi H, Maat-Schieman ML, van Duinen SG, Prins FA, Neeskens P, Natté R, Roos RA. Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropathol Exp Neurol 2000; 59:723-32. [PMID: 10952062 DOI: 10.1093/jnen/59.8.723] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
To clarify where and how beta-amyloid begins to deposit in senile plaques, we examined the ultrastructural localization of amyloid beta protein (Abeta) in diffuse plaques of brains with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Alzheimer disease (AD), and from nondemented aged subjects. Serial ultrathin sections of osmium-plastic blocks were immunogold-labeled for Abetax-42 (Abeta42), and sections on grids were observed under the electron microscope (EM) after observing the exact localization of the diffuse plaques in sections on glass slides by the reflection contrast microscope. Abeta42 deposition, which was decollated with gold particles, appeared in 3 forms in all subjects under the EM: 1) Scattered small bundles of amyloid fibrils between cell processes, frequently seen in the densely stained area of diffuse plaques. 2) Scattered small foci of nonfibrillar materials between cell processes as a relatively minor form. 3) Abeta42 on a part of the cell surface plasma membrane of normal appearing cell processes, a major form in weakly immunostained areas. The last form was not associated with degenerative neurites or reactive glia. Abeta42 deposition on the cell surface plasma membrane appears to be an initial event in diffuse plaques, and then it develops into amorphous/fibrillar amyloid between cell processes.
Collapse
Affiliation(s)
- H Yamaguchi
- Gunma University School of Health Sciences, Maebashi, Japan
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
The integrity of the cerebral vasculature is crucial to the maintenance of cognitive functions during ageing. Prevailing evidence suggests that cerebrovascular functions decline during normal ageing, with pronounced effects in Alzheimer's disease (AD). The causes of these changes largely remain unknown. While previous studies recorded ageing-related impairments, such as atherosclerosis and loss of innervation in basal surface arteries of the brain, it only recently has been realized that a number of subtle alterations in both the intracranial resistance vessels and the smaller capillaries is apparent in both ageing animals and humans. The dominant changes include alterations in composition of connective tissues and smooth muscle of large vessel walls, thickening of the vascular basement membrane, thinning of the endothelium in some species, loss of endothelial mitochondria and increased pericytes. Some of these attributes appear more affected in AD. Other abnormalities entail profound irregularities in the course of microvessels, unexplained inclusions in the basement membrane and changes in unique proteins and membrane lipids associated with the blood-brain barrier. Brain imaging and permeability studies show no clear functional evidence to support the structural and biochemical anomalies, but it is plausible that focal and transient breach of the blood-brain barrier in ageing, and more notably in AD, occurs. Thus, circumscribed neuronal populations in certain brain regions could become vulnerable. Furthermore, the characteristic deposition of amyloid in vessels in AD may exacerbate the decline in vascular function and promote chronic hypoperfusion. Although not explicit from current studies, it is likely that the brain vasculature is continually modified by growth and repair mechanisms in attempts to maintain perfusion during ageing and disease.
Collapse
Affiliation(s)
- R N Kalaria
- Department of Neurology, Case Western Reserve University School of Medicine (BRB5), Cleveland, OH 44106, USA
| |
Collapse
|
15
|
Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA. Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol 1994; 88:371-8. [PMID: 7839831 DOI: 10.1007/bf00310382] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Plaque-like lesions and amyloid angiopathy were investigated in the frontal cerebral cortex of four patients with hereditary cerebral hemorrhage with amyloidosis (Dutch) (HCHWA-D), using immunohistochemical [antibodies to beta amyloid protein (A beta), beta protein precursor (beta PP), synaptophysin, ubiquitin (UBQ), cathepsin D, paired helical filaments (PHF) and glial fibrillary acidic protein (GFAP)], enzymehistochemical (acid phosphatase) and silver [methenamine silver (MS) and Palmgren] staining methods. Whereas A beta- and MS-positive diffuse plaques were found in all patients, only the three older patients showed neuritic or congophilic plaques, which were acid phosphatase and cathepsin D positive and contained beta PP-, synaptophysin- and UBQ-positive, but PHF-negative neurites. These plaques were surrounded by reactive astrocytes. Similar immuno- and enzymereactivity was found around congophilic blood vessels. Thus, apart from neuronal degeneration in a subset of plaque-like lesions and around blood vessels, this study shows an age-related morphology of the plaques in HCHWA-D, corresponding to that in Down's syndrome (DS), with the difference that neurofibrillary (NF) pathology is absent in HCHWA-D in contrast to DS. HCHWA-D may be considered as a model for congophilic plaque formation not associated with NF pathology.
Collapse
Affiliation(s)
- M L Maat-Schieman
- Department of Neurology, University Hospital, Leiden, The Netherlands
| | | | | | | | | |
Collapse
|